Pharming Group N.V. (PHAR) P/E Ratio History
Premium ValuationTrading at 333.5x vs 5Y avg 253.8x · 82th percentile · Premium to historical baseline · Data 2020–2026
Loading P/E history...
P/E Ratio Analysis
As of June 28, 2026, Pharming Group N.V. (PHAR) trades at a price-to-earnings ratio of 333.5x, with a stock price of $13.34 and trailing twelve-month earnings per share of $75.66.
The current P/E is 31% above its 5-year average of 253.8x. Over the past five years, PHAR's P/E has ranged from a low of 27.8x to a high of 1812.5x, placing the current valuation at the 82th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.0x, PHAR trades at a 1349% premium to its sector peers. The sector includes 231 companies with P/E ratios ranging from 0.0x to 191.4x.
Relative to the broader market, PHAR commands a significant premium over the S&P 500 median P/E of 25.3x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our PHAR DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
PHAR Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
PHAR P/E vs Peers
Commercial Rare Disease Biopharma peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $6B | 49.5 | -Best | +2886%Best | |
| $4B | 11.1Lowest | -Best | +68% | |
| $11B | 54.4 | -Best | +128% | |
| $39B | 125.1 | -Best | +207% | |
| $11B | 32.8 | -Best | -19% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
PHAR Historical P/E Data (2020–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q1 | - | $16.64 | $0.17 | 95.1x | -63% |
| FY2025 Q4 | Dec 31 2025 | $17.67 | $0.03 | 589.0x | +132% |
| FY2025 Q3 | - | $14.50 | $0.01 | 1812.5x | +614% |
| FY2022 Q4 | Dec 31 2022 | $11.03 | $0.14 | 78.8x | -69% |
| FY2022 Q3 | Sep 30 2022 | $9.84 | $0.34 | 28.8x | -89% |
| FY2022 Q2 | - | $8.76 | $0.30 | 29.0x | -89% |
| FY2022 Q1 | - | $8.99 | $0.22 | 40.6x | -84% |
| FY2021 Q4 | Dec 31 2021 | $8.94 | $0.32 | 27.8x | -89% |
| FY2021 Q2 | Jun 30 2021 | $11.27 | $0.40 | 28.4x | -89% |
| FY2021 Q1 | Mar 31 2021 | $12.83 | $0.46 | 28.1x | -89% |
| FY2020 Q4 | - | $15.20 | $0.45 | 33.6x | -87% |
Average P/E for displayed period: 253.8x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
6+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
PHAR — Frequently Asked Questions
Quick answers to the most common questions about buying PHAR stock.
What is PHAR's P/E ratio?
Pharming Group N.V. (PHAR) trailing twelve-month P/E ratio is 333.5x, based on TTM diluted EPS of $75.66. The 5-year average P/E is 253.8x and the historical range spans 27.8x to 1812.5x.
Is PHAR stock overvalued or undervalued?
PHAR trades at 333.5x P/E, above its 5-year average of 253.8x. The 82th percentile ranking within the 27.8x–1812.5x historical range indicates a premium to historical valuation.
Is PHAR stock expensive?
Yes, PHAR is expensive relative to its own history. The current P/E of 333.5x is above the 5-year average of 253.8x and also above the Healthcare sector median of 23.0x. The stock sits at the 82th percentile of its 5-year valuation range.
What is PHAR's historical P/E range?
Over the past 5 years, PHAR's P/E ratio has ranged from 27.8x to 1812.5x, with a median of 33.6x and an average of 253.8x. The current P/E of 333.5x places the stock at the 82th percentile of this range. Full historical data spans 2020–2026.
How does PHAR's P/E compare to the S&P 500?
PHAR trades at 333.5x P/E versus the S&P 500 median of 25.3x. The 1218% premium to the market typically reflects higher expected earnings growth or quality.
How does PHAR's valuation compare to Healthcare peers?
Pharming Group N.V. P/E of 333.5x compares to the Healthcare sector median of 23.0x. The premium reflects expected growth above peers or stronger fundamentals. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is PHAR's PEG ratio?
PHAR PEG ratio is N/A, based on a P/E of 333.5x and EPS growth of 123.5%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is PHAR's earnings yield?
PHAR earnings yield is 0.30%, the inverse of its 333.5x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.